Nanosonics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Nanosonics wird ein jährliches Gewinn- und Umsatzwachstum von 24.2% bzw. 10.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 23.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.5% betragen.

Wichtige Informationen

24.2%

Wachstumsrate der Gewinne

23.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.2%
Wachstumsrate der Einnahmen	10.1%
Zukünftige Eigenkapitalrendite	12.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For Nanosonics Limited (ASX:NAN) Suggests It's 21% Undervalued

Mar 30

Returns On Capital - An Important Metric For Nanosonics (ASX:NAN)

Mar 15

Time To Worry? Analysts Are Downgrading Their Nanosonics Limited (ASX:NAN) Outlook

Feb 28

Nanosonics Limited's (ASX:NAN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Feb 19

Is There Now An Opportunity In Nanosonics Limited (ASX:NAN)?

Feb 07

What Did Nanosonics' (ASX:NAN) CEO Take Home Last Year?

Jan 26

How Much Of Nanosonics Limited (ASX:NAN) Do Insiders Own?

Jan 14

Here's Why Nanosonics's (ASX:NAN) Statutory Earnings Are Arguably Too Conservative

Jan 01

Estimating The Intrinsic Value Of Nanosonics Limited (ASX:NAN)

Dec 20

Is There More Growth In Store For Nanosonics' (ASX:NAN) Returns On Capital?

Dec 07

Can You Imagine How Elated Nanosonics' (ASX:NAN) Shareholders Feel About Its 302% Share Price Gain?

Nov 25

Gewinn- und Umsatzwachstumsprognosen

ASX:NAN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2026	208	19	20	26	10
6/30/2025	192	13	12	17	12
6/30/2024	167	8	15	18	12
12/31/2023	164	16	22	24	N/A
9/30/2023	165	18	21	24	N/A
6/30/2023	166	20	20	23	N/A
3/31/2023	154	15	15	20	N/A
12/31/2022	141	10	10	16	N/A
9/30/2022	131	7	5	11	N/A
6/30/2022	120	4	0	7	N/A
3/31/2022	120	7	2	7	N/A
12/31/2021	121	11	4	8	N/A
9/30/2021	112	10	5	8	N/A
6/30/2021	103	9	6	7	N/A
3/31/2021	99	7	7	9	N/A
12/31/2020	95	6	8	10	N/A
9/30/2020	97	8	15	16	N/A
6/30/2020	100	10	21	23	N/A
3/31/2020	96	11	16	18	N/A
12/31/2019	92	12	11	13	N/A
9/30/2019	88	13	7	9	N/A
6/30/2019	84	14	3	5	N/A
3/31/2019	78	12	3	6	N/A
12/31/2018	71	11	4	6	N/A
9/30/2018	66	8	5	8	N/A
6/30/2018	61	6	6	9	N/A
3/31/2018	61	6	8	11	N/A
12/31/2017	61	6	11	13	N/A
9/30/2017	64	16	N/A	15	N/A
6/30/2017	68	26	N/A	16	N/A
3/31/2017	65	26	N/A	16	N/A
12/31/2016	63	25	N/A	16	N/A
9/30/2016	53	13	N/A	10	N/A
6/30/2016	43	0	N/A	3	N/A
3/31/2016	33	-5	N/A	-3	N/A
12/31/2015	23	-10	N/A	-8	N/A
9/30/2015	23	-8	N/A	-5	N/A
6/30/2015	22	-5	N/A	-2	N/A
3/31/2015	24	-2	N/A	0	N/A
12/31/2014	26	2	N/A	2	N/A
9/30/2014	24	0	N/A	0	N/A
6/30/2014	21	-3	N/A	-3	N/A
3/31/2014	21	-3	N/A	-3	N/A
12/31/2013	20	-3	N/A	-3	N/A
9/30/2013	18	-4	N/A	-4	N/A
6/30/2013	15	-6	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NANDas prognostizierte Gewinnwachstum (24.2% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: NANDie Erträge des Unternehmens (24.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (13.7% pro Jahr).

Hohe Wachstumserträge: NANEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: NANDie Einnahmen des Unternehmens (10.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.4% pro Jahr).

Hohe Wachstumseinnahmen: NANDie Einnahmen des Unternehmens (10.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NANDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.5%).

Nanosonics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 22%, revenue upgraded

Consensus EPS estimates increase by 16%

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 25%

Consensus forecasts updated

Recent updates

Independent Non-Executive Director recently sold AU$304k worth of stock

New minor risk - Insider selling

Key Executive recently bought AU$100k worth of stock

Returns On Capital At Nanosonics (ASX:NAN) Paint A Concerning Picture

First half 2024 earnings released: EPS: AU$0.02 (vs AU$0.034 in 1H 2023)

Some Confidence Is Lacking In Nanosonics Limited (ASX:NAN) As Shares Slide 33%

Now 37% undervalued after recent price drop

Consensus EPS estimates fall by 15%

Nanosonics Limited to Report First Half, 2024 Results on Feb 26, 2024

Is Nanosonics Limited (ASX:NAN) Potentially Undervalued?

Now 20% undervalued after recent price drop

Investors Will Want Nanosonics' (ASX:NAN) Growth In ROCE To Persist

Now 20% undervalued after recent price drop

Nanosonics Limited Announces Appointment of Jason Burriss as Chief Financial Officer, Effective 3 October 2023

Consensus EPS estimates fall by 22%, revenue upgraded

Nanosonics Limited Appoints Larry Marshall as Non- Executive Director, Effective from 3 October 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Nanosonics Limited, Annual General Meeting, Nov 03, 2023

Nanosonics Limited to Report Fiscal Year 2023 Results on Aug 22, 2023

Nanosonics Limited Announces the Appointment of Tracey Batten as Non-Executive Director, Effective 26 September 2023

Is Nanosonics Limited (ASX:NAN) Potentially Undervalued?

CEO, President recently sold AU$121k worth of stock

Nanosonics (ASX:NAN) Will Be Hoping To Turn Its Returns On Capital Around

Nanosonics Announces Company Secretary Changes

Independent Non-Executive Director recently sold AU$504k worth of stock

First half 2023 earnings: Revenues in line with analyst expectations

Consensus EPS estimates increase by 16%

Nanosonics Limited to Report First Half, 2023 Results on Feb 23, 2023

Consensus EPS estimates increase by 11%

Is Now The Time To Look At Buying Nanosonics Limited (ASX:NAN)?

Consensus EPS estimates increase by 25%

Insufficient new directors

Insufficient new directors

This Is Why Nanosonics Limited's (ASX:NAN) CEO Compensation Looks Appropriate

A Look At The Fair Value Of Nanosonics Limited (ASX:NAN)

What Does Nanosonics Limited's (ASX:NAN) Share Price Indicate?

Now 20% undervalued

CEO, President recently sold AU$960k worth of stock

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations

Nanosonics Limited, Annual General Meeting, Nov 18, 2022

Nanosonics Limited to Report Fiscal Year 2022 Results on Aug 23, 2022

Insufficient new directors

Consensus estimates of losses per share improve by 40%

Nanosonics Limited Provides Revenue Guidance for the Fiscal Year 2022

A Look At The Fair Value Of Nanosonics Limited (ASX:NAN)

Now 21% undervalued after recent price drop

At AU$3.36, Is Nanosonics Limited (ASX:NAN) Worth Looking At Closely?

Nanosonics (ASX:NAN) Will Want To Turn Around Its Return Trends

Now 21% undervalued after recent price drop

Nanosonics Limited Announces Management Changes

Price target decreased to AU$4.79

A Look At The Intrinsic Value Of Nanosonics Limited (ASX:NAN)

Consensus EPS estimates have been downgraded.

First half 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates fall by 11%

Nanosonics Limited to Report First Half, 2022 Results on Feb 22, 2022

Nanosonics Limited (ASX:NAN) Analysts Just Cut Their EPS Forecasts

Consensus EPS estimates fall by 46%

Is Now The Time To Look At Buying Nanosonics Limited (ASX:NAN)?

Nanosonics Limited's (ASX:NAN) CEO Looks Due For A Compensation Raise

Price target increased to AU$5.87

Nanosonics Limited Provides Earnings Guidance for the Fiscal Year 2022

Full year 2021 earnings released: EPS AU$0.029 (vs AU$0.034 in FY 2020)

Consensus forecasts updated

Returns Are Gaining Momentum At Nanosonics (ASX:NAN)

Consensus forecasts updated

Consensus forecasts updated

Nanosonics to Launch Digital Platform for Infection Control